• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

临床代谢组学及其在冠心病诊疗中的研究进展

殷锟鹏, 郑好, 谢滨新, 李萍, 张蕾, 范勇, 朱伟, 齐炼文

殷锟鹏, 郑好, 谢滨新, 李萍, 张蕾, 范勇, 朱伟, 齐炼文. 临床代谢组学及其在冠心病诊疗中的研究进展[J]. 中国药科大学学报, 2017, 48(6): 629-634. DOI: 10.11665/j.issn.1000-5048.20170601
引用本文: 殷锟鹏, 郑好, 谢滨新, 李萍, 张蕾, 范勇, 朱伟, 齐炼文. 临床代谢组学及其在冠心病诊疗中的研究进展[J]. 中国药科大学学报, 2017, 48(6): 629-634. DOI: 10.11665/j.issn.1000-5048.20170601
YIN Kunpeng, ZHENG Hao, XIE Binxin, LI Ping, ZHANG Lei, FAN Yong, ZHU Wei, QI Lianwen. Clinical metabolomics in diagnosis and therapy of coronary artery disease[J]. Journal of China Pharmaceutical University, 2017, 48(6): 629-634. DOI: 10.11665/j.issn.1000-5048.20170601
Citation: YIN Kunpeng, ZHENG Hao, XIE Binxin, LI Ping, ZHANG Lei, FAN Yong, ZHU Wei, QI Lianwen. Clinical metabolomics in diagnosis and therapy of coronary artery disease[J]. Journal of China Pharmaceutical University, 2017, 48(6): 629-634. DOI: 10.11665/j.issn.1000-5048.20170601

临床代谢组学及其在冠心病诊疗中的研究进展

基金项目: 国家自然科学基金资助项目(No.91639115)

Clinical metabolomics in diagnosis and therapy of coronary artery disease

  • 摘要: 代谢组学是近年来生命科学的热门研究领域,它通过分析生物样品中的代谢物,从机体水平上揭示疾病代谢紊乱特征。越来越多的研究证实将代谢组学运用于临床诊疗的可行性,检测生物体液的“代谢指纹”可以为疾病预防、早期诊断、精准治疗、预后评估和新药发现等提供重要支撑。由此,临床代谢组学(clinical metabolomics)应运而生。临床代谢组学是指结合临床大样本,采用代谢组学和生物信息学等手段,从整体上描绘内源性代谢小分子集合在疾病扰动下的稳态失衡及药物干预下的转归机制,揭示疾病潜在的诊疗生物标志物和可干预靶标的一门学科。本文从临床代谢组学发展历程切入,简述了其分析技术手段和研究内容,并以冠心病为例,总结了临床代谢组学在疾病诊疗中的研究进展。
    Abstract: Metabolomics, a hot field of research of life science in recent years, is to analyze endogenous small-molecule metabolites in biological samples for an overall understanding of the characteristics of metabolic disorders. A growing number of studies have confirmed the application of metabolomics for clinical diagnosis and treatment of diseases. “Metabolic fingerprint” of biological fluids can be employed for disease prevention, timely diagnosis, accurate treatment, prognostic assessment and drug discovery. Clinical metabolomics is to measure low-molecule-weight metabolites′ alterations of individuals in response to physiological stressors, disease processes, or drug therapy, aiming to discover potential biomarkers and drug targets. Coronary artery disease(CAD)is characterized as complex molecular events. Metabolic disturbances are involved in CAD progression. The application of metabolomics to CAD is an emerging field. Advances in metabolomics improve our knowledge on CAD in early diagnosis, prognostic prediction, and personalized therapy.
  • [1] Zhao JX,Tian YX.Huang Di Nei Jing(黄帝内经)[M].Beijing:Jinghua Press,2013:314-320.
    [2] Zbek A,Junka A,Szymczyk P,et al.Metabolomics analysis of fungal biofilm development and of arachidonic acid-based quorum sensing mechanism[J].J Basic Microb,2017,57(5):428-439.
    [3] Lee YJ,Perdian DC,Song Z,et al.Use of mass spectrometry for imaging metabolites in plants[J].Plant J,2012,70(1):81-85.
    [4] Hong JH,Lee WC,Hsu YM,et al.Characterization of the biochemical effects of naphthalene on the mouse respiratory system using NMR-based metabolomics[J].J Appl Toxicol,2015,34(12):1379-1388.
    [5] Heather LC, Wang X, West JA, et al. A practical guide to metabolomic profiling as a discovery tool for human heart disease[J].J Mol Cell Cardiol,2013,55(2):2-11.
    [6] Kobayashi T,Nishiumi S,Ikeda A,et al.A novel serum metabolomics-based diagnostic approach to pancreatic cancer[J].Cancer Epidem Biomar,2013,22(4):571-579.
    [7] Floegel A,Stefan N,Yu Z,et al.Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach[J].Diabetes,2013,62(2):639-648.
    [8] Paglia G,Stocchero M,Cacciatore S,et al.An unbiased metabolomic investigation of the Alzheimer′s disease brain points to a dysregulation of the mitochondrial aspartate metabolism[J].J Proteome Res,2015,15(2):1334-1341.
    [9] Tang H,Wang Y.Metabonomics:a revolution in progress[J].Prog Biochem Biophys,2006,33(5):401-417.
    [10] Nicholson JK,Lindon JC,Holmes E.‘Metabonomics’:understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data[J].Xenobiotica,1999,29(11):1181-1189.
    [11] Brindle JT,Antti H,Holmes E,et al.Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics[J].Nat Med,2002,8(12):1439-1444.
    [12] Fan Y,Li Y,Chen Y,et al.Comprehensive metabolomic characterization of coronary artery diseases[J].J Am Coll Cardiol,2016,68(12):1281-1293.
    [13] Nicholson JK,Buckingham MJ,Sadler PJ.High resolution 1H n.m.r.studies of vertebrate blood and plasma[J].Biochem J,1983,211(3):605-615.
    [14] Qiu QQ,Yan M,Li C.Advances in analytic technology of metabolomics [J].J Diagn Concepts Pract(诊断学理论与实践),2011,10(1):82-85.
    [15] Bathen TF,Sitter B,Sjøbakk TE,et al.Magnetic resonance metabolomics of intact tissue:a biotechnological tool in cancer diagnostics and treatment evaluation[J].Cancer Res,2010,70(17):6692-6696.
    [16] Bernini P,Bertini I,Luchinat C,et al.The cardiovascular risk of healthy individuals studied by NMR metabonomics of plasma samples[J].J Proteome Res,2011,10(11):4983-4992.
    [17] Soininen P,Kangas AJ,Würtz P,et al.Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics[J].Circ Cardiovasc Genet,2015,8(1):192-206.
    [18] Wang J,Yuan ZM,Kong HW,et al.Exploring the mechanism of Rhizoma coptidis in treating type II diabetes mellitus based on metabolomics by gas chromatography-mass spectrometry[J].Chin J Chromatogr(色谱),2012,30(1):8-13.
    [19] Tachibana C.What′s next in ′omics:the metabolome[J].Science,2014,345(6203):1519-1521.
    [20] Yong F,Xin Z,Xia TS,et al.Human plasma metabolomics for identifying differential metabolites and predicting molecular subtypes of breast cancer[J].Oncotarget,2016,7(9):9925-9938.
    [21] World Health Organization.Cardiovascular disease(CVDs)[EB/OL].(2017-05-01)[2017-11-13] .http://www.who.int/mediacentre/factsheets/fs317/en.
    [22] Moran A,Gu D,Zhao D,et al.Future cardiovascular disease in China Markov model and risk factor scenario projections from the coronary heart disease policy model-China [J].Circ Cardiocasc Qual Outcomes,2010,3(3):243-252.
    [23] Mertens A,Verhamme P,Bielicki JK,et al.Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice[J].Circulation,2003,107(12):1640-1646.
    [24] Falk E.Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis.Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi[J].Brit Heart J,1983,50(2):127-134.
    [25] Schwartz SM.Perspectives series:cell adhesion in vascular biology.Smooth muscle migration in atherosclerosis and restenosis[J].J Clin Invest,1997,99(12):2814-2817.
    [26] Jiang P.The Study on Metabolomics and pharmacokinetics of Shexiang Baoxin Pill(麝香保心丸代谢组学和代谢动力学研究)[D].Shanghai:The Second Military Medical University,2012.
    [27] Barba I,León GD,Martín E,et al.Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease[J].Magnet Reson Med,2008,60(1):27-32.
    [28] Sabatine MS,Liu E,Morrow DA,et al.Metabolomic identification of novel biomarkers of myocardial ischemia[J].Circulation,2005,112(25):3868-3875.
    [29] Evans AM,Dehaven CD,Barrett T,et al.Integrated,nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems[J].Anal Chem,2009,81(16):6656-6667.
    [30] Forcisi S,Moritz F,Kanawati B,et al.Liquid chromatography-mass spectrometry in metabolomics research:mass analyzers in ultra high pressure liquid chromatography coupling[J].J Chromatogr A,2013,1292(5):51-65.
    [31] Lewis GD,Wei R,Liu E,et al.Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury[J].J Clin Invest,2008,118(10):3503-3512.
    [32] Li J,Yang YL,Li LZ,et al.Succinate accumulation impairs cardiac pyruvate dehydrogenase activity through GRP91-dependent and independent signaling pathways:therapeutic effects of ginsenoside Rb1[J].BBA-Mol Basis Dis,2017,1863(11):2835-2847.
    [33] Vary TC,Reibel DK,Neely JR.Control of energy metabolism of heart muscle[J].Annu Rev Physiol,1981,43(5):419-430.
    [34] Young LH,Mcnulty PH,Morgan C,et al.Myocardial protein turnover in patients with coronary artery disease.Effect of branched chain amino acid infusion[J].J Clin Invest,1991,87(2):554-560.
    [35] Drake KJ,Sidorov VY,Mcguinness OP,et al.Amino acids as metabolic substrates during cardiac ischemia[J].Exp Biol Med,2012,237(12):1369-1378.
    [36] Yang R,Dong J,Zhao H,et al.Association of branched-chain amino acids with carotid intima-media thickness and coronary artery disease risk factors[J].PLoS ONE,2014,9(6):e99598.
    [37] Yang R, Wang S, Sun L, et al. Association of branched-chain amino acids with coronary artery disease:a matched-pair case-control study[J].Nutr Metab Cardiovas,2015,25(10):937-942.
    [38] Bernini P,Bertini I,Luchinat C,et al.The cardiovascular risk of healthy individuals studied by NMR metabonomics of plasma samples[J].J Proteome Res,2011,10(11):4983-4992.
    [39] Patel MR,Peterson ED,Dai D,et al.Low diagnostic yield of elective coronary angiography[J].New Engl J Med,2010,362(10):886-895.
    [40] Wang Z,Elizabeth K,Bennett BJ,et al.Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease[J].Nature,2011,472(7341):57-63.
    [41] Erdmann CC.Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk[J].New Engl J Med,2013,368(17):1575-1584.
    [42] Tang WH,Hazen SL.The contributory role of gut microbiota in cardiovascular disease[J].J Clin Invest,2014,124(10):4204-4211.
    [43] Wang Z,Roberts AB,Buffa JA,et al.Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis[J].Cell,2015,163(7):1585-1595.
    [44] Suhre K,Shin SY,Petersen AK,et al.Human metabolic individuality in biomedical and pharmaceutical research[J].Nature,2011,477(7362):54-60.
    [45] Wishart DS.Emerging applications of metabolomics in drug discovery and precision medicine[J].Nat Rev Drug Discov,2016,15(7):473-484.
  • 期刊类型引用(3)

    1. 任萌,刘菲,张辉,杨素珍,焦雅培,王先浩,苏蓓,李晓彤. 透明质酸的性能及其载体化应用. 山东化工. 2024(10): 112-117+120 . 百度学术
    2. 侯效英,高帆,杜丽东,王瑞琼,吴国泰. 藁本内酯稳定性研究进展. 中国药学杂志. 2024(24): 2299-2305 . 百度学术
    3. 高雷雷,王芳,陈艳君,王威,李国四,韩邦兴,刘东. OBE教育理念下药物化学实验设计:双丹皮酚缩1, 3-丙二胺席夫碱的合成. 广东化工. 2023(24): 145-147 . 百度学术

    其他类型引用(1)

计量
  • 文章访问数:  1014
  • HTML全文浏览量:  5
  • PDF下载量:  2337
  • 被引次数: 4
出版历程
  • 刊出日期:  2017-12-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭